Elon Musk microdoses ketamine to treat depression: report
Elon Musk Uses Ketamine to Treat Depression and Takes Special K at Parties, Report Claims
In a shocking report released on Tuesday, it has been alleged that Elon Musk, the CEO of Tesla, Twitter, and Space X, uses small doses of ketamine to treat his depression. The report, published by the Wall Street Journal, reveals that Musk also occasionally takes full doses of Special K, a popular club drug, when he attends parties. This revelation is part of a growing trend among Silicon Valley executives who experiment with recreational use of psychedelics, believing that it enhances their business performance and creativity.
Ketamine, a tranquilizer with hallucinogenic qualities that is typically prescribed by veterinarians, has gained popularity as an alternative treatment for depression. Musk has openly talked about microdosing ketamine for depression and has defended the benefits of the drug on his social media platform. In the wake of the Journal’s report, Musk took to Twitter to express his thoughts on depression and the use of antidepressants. He stated, “Depression is overdiagnosed in the US, but for some people, it really is a brain chemistry issue. But zombifying people with SSRIs for sure happens way too much.”
Musk’s close friend and Google co-founder Sergey Brin was also mentioned in the report. According to witnesses, Brin has experimented with magic mushrooms, which contain the hallucinogenic chemical psilocybin. Clinical trials have shown that psilocybin and LSD have benefits in treating depression and other mental health conditions. However, Brin has not made any public comments on his alleged drug use.
The Wall Street Journal further uncovered an underground network of tech-centric parties and social gatherings where executives indulge in various hallucinogenic drugs. Some parties reportedly hire chemists to provide the drugs, while others rely on drug dealers. The report mentioned Founders Fund, a prominent venture capital firm co-founded by Peter Thiel, that allegedly threw exclusive parties involving psychedelic drug use. A spokesperson for Founders Fund stated that they support efforts to make these drugs safely and legally available, citing research showcasing their potential mental health benefits.
One CEO, Spencer Shulem of the startup firm BuildBetter.ai, revealed that he credits his use of LSD with helping him concentrate and think creatively. Shulem takes LSD once every three months and believes that it gives him an edge over his competitors in the tech industry. However, he clarified that he does not advocate for drug use among his employees.
As this report continues to generate controversy and speculation, it remains to be seen how the tech industry and the public will respond to the alleged drug habits of Elon Musk and other Silicon Valley executives.
FAQs:
1. What is ketamine, and why is it used?
Ketamine is a tranquilizer that is primarily used as an anesthetic in medical settings. It has also gained recognition for its potential to treat depression and other mental health conditions.
2. What is microdosing?
Microdosing refers to taking very small doses of a substance, such as psychedelics, to experience subtle effects without full hallucinations.
3. What is Special K?
Special K is a street name for ketamine. It is commonly used as a recreational drug due to its hallucinogenic properties.
4. Are psychedelics legal?
The legal status of psychedelics varies by country and region. In some places, they are classified as controlled substances, while others have made efforts to decriminalize or legalize them for medicinal or therapeutic purposes.
5. How have psychedelics been studied for mental health benefits?
Various clinical trials have explored the potential benefits of psychedelics like psilocybin and LSD in treating depression, anxiety, PTSD, and other mental health conditions. These studies have shown promising results, but further research is still needed.
6. Is there a trend of psychedelic drug use among Silicon Valley executives?
According to the Wall Street Journal report, there is a growing trend of Silicon Valley executives experimenting with psychedelics, believing that it enhances their business performance and creativity.
7. What has been the response to this report?
The responses to the report have varied. Some individuals argue that psychedelics can provide significant mental health benefits and should be explored further, while others criticize the alleged drug use of tech industry leaders. The impact on their businesses and public perception is yet to be determined.
Report: Elon Musk Utilizes Ketamine Microdosing for Depression Treatment
Tech billionaire Elon Musk reportedly utilizes small doses of ketamine to treat depression and occasionally indulges in full doses of the drug, known as Special K, at parties, according to a recent report by the Wall Street Journal. This alleged drug use by Musk, the CEO of Tesla, Twitter, and SpaceX, is part of a rising trend among Silicon Valley executives who experiment with psychedelic drugs for their perceived benefits in boosting creativity and business performance.
Ketamine, typically prescribed by veterinarians as a tranquilizer with hallucinogenic effects, has gained popularity as an alternative treatment for depression. Musk took to social media to defend his use of the drug, stating that depression is often overdiagnosed in the US and that ketamine, when taken occasionally, can be a better option than traditional antidepressants. Other Wall Street and tech tycoons, such as Google co-founder Sergey Brin, have also been associated with the use of hallucinogenic substances like magic mushrooms and LSD for their potential mental health benefits.
The Wall Street Journal’s report also sheds light on the presence of an underground party scene in the tech industry, where executives engage in drug use, sometimes purchasing hallucinogens from dealers. Founders Fund, a well-known venture capital firm based in San Francisco, has allegedly hosted exclusive events that feature psychedelic drug use.
Some individuals within the tech industry claim that psychedelics enhance their focus and creativity. Spencer Shulem, CEO of the startup firm BuildBetter.ai, credits his occasional use of LSD with helping him think more creatively and gain an edge over competitors in securing venture capital. However, Shulem emphasizes that he does not actively promote drug use among his employees.
The growing interest in psychedelic substances among Silicon Valley executives has sparked discussions about the potential benefits of these drugs and the need for further research to explore their therapeutic properties.